Amicus Q4 revenue beats estimates

Reuters02-21

Amicus Q4 revenue beats estimates

Overview

Biotechnology firm's Q4 revenue rose 24%, beating analyst expectations
Adjusted EPS for Q4 beat analyst expectations

Outlook

Company will not provide financial guidance for 2026 due to pending acquisition

Result Drivers

GALAFOLD SALES - Driven by commercial execution, new patient starts, and strong compliance
POMBILITI + OPFOLDA SALES - High demand from established and new markets drove growth
CASH POSITION - Increased by $44M, reflecting operational growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$185.20 mln	$180.69 mln (9 Analysts)
Q4 Adjusted EPS	Beat	$0.10	$0.09 (8 Analysts)
Q4 EPS		$0.01
Q4 Net Income		$1.70 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Amicus Therapeutics Inc is $14.50, about 1% above its February 19 closing price of $14.35
The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months ago

Press Release: ID:nGNX8znCKR

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613975322?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-21 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613975322","market":"nz","top_or_hot":-1,"title":"Amicus Q4 revenue beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Amicus Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biotechnology firm's Q4 revenue rose 24%, beating analyst expectations</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company will not provide financial guidance for 2026 due to pending acquisition</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GALAFOLD SALES - Driven by commercial execution, new patient starts, and strong compliance</p></li><li><p>POMBILITI + OPFOLDA SALES - High demand from established and new markets drove growth</p></li><li><p>CASH POSITION - Increased by $44M, reflecting operational growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$185.20 mln</p></td><td><p>$180.69 mln (9 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.10</p></td><td><p>$0.09 (8 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$0.01</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$1.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 7 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Amicus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $14.50, about 1% above its February 19 closing price of $14.35</p></li><li><p>The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX8znCKR</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amicus Q4 revenue beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmicus Q4 revenue beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-21 05:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Amicus Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biotechnology firm's Q4 revenue rose 24%, beating analyst expectations</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company will not provide financial guidance for 2026 due to pending acquisition</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GALAFOLD SALES - Driven by commercial execution, new patient starts, and strong compliance</p></li><li><p>POMBILITI + OPFOLDA SALES - High demand from established and new markets drove growth</p></li><li><p>CASH POSITION - Increased by $44M, reflecting operational growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$185.20 mln</p></td><td><p>$180.69 mln (9 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.10</p></td><td><p>$0.09 (8 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$0.01</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$1.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 7 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Amicus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $14.50, about 1% above its February 19 closing price of $14.35</p></li><li><p>The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX8znCKR</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065170008.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nL1N3ZG0ZF:1","article_id":"2613975322","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613975322","pubTimestamp":1771621816,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amicus Q4 revenue beats estimatesOverviewBiotechnology firm's Q4 revenue rose 24%, beating analyst expectationsAdjusted EPS for Q4 beat analyst expectationsOutlookCompany will not provide financial gu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","FOLD":"爱美医疗","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4139":"生物科技","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"Amicus第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FOLD":0.9},"content_text":"Amicus Q4 revenue beats estimatesOverviewBiotechnology firm's Q4 revenue rose 24%, beating analyst expectationsAdjusted EPS for Q4 beat analyst expectationsOutlookCompany will not provide financial guidance for 2026 due to pending acquisitionResult DriversGALAFOLD SALES - Driven by commercial execution, new patient starts, and strong compliancePOMBILITI + OPFOLDA SALES - High demand from established and new markets drove growthCASH POSITION - Increased by $44M, reflecting operational growthKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$185.20 mln$180.69 mln (9 Analysts)Q4 Adjusted EPSBeat$0.10$0.09 (8 Analysts)Q4 EPS$0.01Q4 Net Income$1.70 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 7 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Amicus Therapeutics Inc is $14.50, about 1% above its February 19 closing price of $14.35The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months agoPress Release: ID:nGNX8znCKRFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613975322","isCrawlerRequest":true}